GLP-1 receptor agonist use does not increase insulin discontinuation… | HappeningNow.news
Published Date: July 16, 2026

Health · 1 views

GLP-1 receptor agonist use does not increase insulin discontinuation with type 2 diabetes

For veterans with type 2 diabetes (T2D) receiving basal insulin therapy, the addition of glucagon-like peptide-1 receptor agonists (GLP-1…

Source Medical Xpress AI Summary Updated 1h 54m ago
Story intelligence Beta
Freshness Fresh Updated 1h 54m ago
Confidence Limited Single-outlet story
Coverage Single outlet
Views 1 Community interest
Read time 1 min ~47 words

AI Summary

For veterans with type 2 diabetes (T2D) receiving basal insulin therapy, the addition of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) does not increase the rate of insulin discontinuation compared with other glucose-lowering agents, according to a study published online July 14 in the Annals of Internal Medicine.

Read full article on Medicalxpress

AI summaries can be wrong sometimes—always verify important details using the source article.

More coverage on this topic

GLP52 stories
View all GLP coverage
SUPPORT HAPPENINGNOW · Independent AI News Intelligence
SUPPORTER MESSAGE

Enjoyed this article? Consider supporting HappeningNow to help keep independent AI-powered news analysis moving forward. Your contribution helps cover infrastructure, AI summaries, and continued platform development.

Support HappeningNow
Category Health
Outlet Medicalxpress
Source Medical Xpress
Return to Frontpage

More from Health

Continue reading recent Health coverage